Intratumor Heterogeneity in Breast Cancer
Intratumor Heterogeneity in Breast Cancer
复制标题
DOI：
10.1007/978-3-319-22909-6_7
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Polyak, Kornelia
中科院分区：
文献类型：
--
作者：
Beca, Francisco;Polyak, Kornelia
肿瘤内异质性是有效癌症治疗和个性化医疗的主要障碍。肿瘤内异质性的遗传和表观遗传来源都是公认的，并且已经开发了几种技术用于其表征。随着近年来技术的进步，研究人员现在正在阐明单细胞水平和原位的肿瘤内异质性。然而，将积累的关于肿瘤内异质性的知识转化为临床实践一直很缓慢。我们确信，更好地了解疾病进展和治疗过程中肿瘤的组成和演变将改善癌症诊断和治疗设计。在这里，我们回顾了一些最重要的考虑有关的肿瘤内异质性。我们讨论了肿瘤内异质性的遗传和表观遗传来源，并回顾了常用的量化方法。我们还讨论了肿瘤内异质性对癌症诊断和治疗的影响，并分享了我们对这一领域未来的看法。
Intratumor heterogeneity is the main obstacle to effective cancer treatment and personalized medicine. Both genetic and epigenetic sources of intratumor heterogeneity are well recognized and several technologies have been developed for their characterization. With the technological advances in recent years, investigators are now elucidating intratumor heterogeneity at the single cell level and in situ. However, translating the accumulated knowledge about intratumor heterogeneity to clinical practice has been slow. We are certain that better understanding of the composition and evolution of tumors during disease progression and treatment will improve cancer diagnosis and the design of therapies. Here we review some of the most important considerations related to intratumor heterogeneity. We discuss both genetic and epigenetic sources of intratumor heterogeneity and review experimental approaches that are commonly used to quantify it. We also discuss the impact of intratumor heterogeneity on cancer diagnosis and treatment and share our perspectives on the future of this field.